The usefulness of the estimated average glucose/fasting blood glucose ratio for pancreatic β-cell function assessment in hyperglycemia during health checkups.

Publisher: Wiley Country of Publication: United States NLM ID: 8801384 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2825 (Electronic) Linking ISSN: 08878013 NLM ISO Abbreviation: J Clin Lab Anal Subsets: MEDLINE

Publication: Hoboken, N.J. : Wiley
Original Publication: New York : Alan R. Liss, Inc., c1987-

Diabetes Mellitus, Type 2* ; Hyperglycemia* ; Insulin Resistance*/physiology ; Prediabetic State*; Blood Glucose ; Cross-Sectional Studies ; Fasting ; Humans ; Insulin

Background: Type 2 diabetes (T2DM) is a disease marked by inadequate insulin secretion by pancreatic beta-cell function (BCF) failure and insulin resistance (IR). Assessing and managing the BCF and IR should be started early to prevent or delay the progression of the disease. The aim of this study was to determine the usefulness of the estimated average glucose (eAG)/fasting blood glucose (FBG) ratio for pancreatic BCF in hyperglycemia.
Methods: This cross-sectional study consecutively selected 10,594 subjects who underwent a health checkup at 16 health checkup centers in 13 Korean cities between 2019 and 2021. The subjects consisted of 3003 patients with normoglycemia, 3413 with impaired fasting glucose and 4178 with T2DM. The eAG was calculated using Nathan's regression equation. BCF and IR were estimated by the homeostasis model assessment (HOMA)-β and HOMA-IR, respectively. Multivariate (adjusted) regression analysis was performed to evaluate the association between the eAG/FBG ratio and HOMA.
Results: The median values among FBG groups for the eAG/FBG ratio, HOMA-β, -IR and insulin differed significantly (p < 0.001). The second-, third- and fourth-quartile groups of the eAG/FBG ratio had positive higher correlation coefficients [9.533, 10.080 and 12.021, respectively (all p < 0.001)] for HOMA-β than the first quartile group, and higher negative coefficients for HOMA-IR [-0.696, -0.727 and -0.598, respectively (all p = 0.001)].
Conclusion: The eAG/FBG ratio was significantly correlated with both HOMA-β and -IR, which suggests that eAG/FBG ratio reveals BCF and IR in hyperglycemia. Measurement of this ratio could be useful for monitoring BCF and IR in prediabetes and T2DM.
(© 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.)

Diabetes Care. 2008 Aug;31(8):1473-8. (PMID: 18540046)
J Clin Lab Anal. 2022 Oct;36(10):e24693. (PMID: 36098986)
Clin Chem Lab Med. 2010 Nov;48(11):1629-34. (PMID: 20704534)
Coron Artery Dis. 2005 Dec;16(8):465-72. (PMID: 16319655)
Biomed Res Int. 2014;2014:370790. (PMID: 25013775)
J Clin Endocrinol Metab. 2006 Feb;91(2):629-34. (PMID: 16317057)
Diabetes Care. 2019 Mar;42(3):416-426. (PMID: 30104301)
Diabetes. 2003 Aug;52(8):2168-74. (PMID: 12882937)
Medicine (Baltimore). 2020 Oct 2;99(40):e22337. (PMID: 33019410)
Diabetes. 2009 Apr;58(4):773-95. (PMID: 19336687)
J Clin Invest. 1999 Sep;104(6):787-94. (PMID: 10491414)
BMJ. 2000 Aug 12;321(7258):405-12. (PMID: 10938048)
Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
Nature. 2019 Dec;576(7785):51-60. (PMID: 31802013)
Diabetes Care. 2013 Jan;36 Suppl 1:S11-66. (PMID: 23264422)
Lancet. 2005 Apr 9-15;365(9467):1333-46. (PMID: 15823385)
Nat Rev Endocrinol. 2018 Feb;14(2):88-98. (PMID: 29219149)
Curr Diabetes Rev. 2014 Jan;10(1):2-42. (PMID: 24524730)
Clin Chem. 2011 Feb;57(2):205-14. (PMID: 21148304)
Front Endocrinol (Lausanne). 2013 Mar 27;4:37. (PMID: 23542897)
Diabetes Care. 2011 Jan;34 Suppl 1:S11-61. (PMID: 21193625)
Clin Chem Lab Med. 2013 Nov;51(11):2195-200. (PMID: 24057595)
Scand J Clin Lab Invest. 2022 May;82(3):192-198. (PMID: 35175156)
Diabetes Care. 2004 Jun;27(6):1487-95. (PMID: 15161807)
Diabetologia. 2003 Jan;46(1):3-19. (PMID: 12637977)
Diabetes Care. 2007 Sep;30(9):2399-400. (PMID: 17726190)

Keywords: eAG/FBG ratio; homeostasis model assessment; insulin resistance; pancreatic β-cell function; type 2 diabetes

0 (Blood Glucose)
0 (Insulin)

Date Created: 20220913 Date Completed: 20221012 Latest Revision: 20240905

20250114

PMC9550971

10.1002/jcla.24693

36098986